<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01884831</url>
  </required_header>
  <id_info>
    <org_study_id>USMA01082012</org_study_id>
    <nct_id>NCT01884831</nct_id>
  </id_info>
  <brief_title>The Study of the Effectiveness of Tissue Equivalent on the Basis of Cultured Cells to Heal Skin Blemishes</brief_title>
  <acronym>SETES</acronym>
  <official_title>Phase 2 The Use of Tissue-equivalent Based on Cultured Cells for Healing Skin Blemishes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ural State Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ural State Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Russia the treatment nonhealing skin defects often limited to surgical interventions,&#xD;
      despite having developed modern methods of treatment of non-healing ulcers and other skin&#xD;
      imperfections. During the many years of research we have developed a skin equivalent&#xD;
      comprising living cells.&#xD;
&#xD;
      During pilot trial showed that the skin equivalent provides healing skin defect within 1-4&#xD;
      weeks in 95% of patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficiency</measure>
    <time_frame>six weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Neurotrophic Ulcers</condition>
  <condition>Burns</condition>
  <arm_group>
    <arm_group_label>cell therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>study of the efficacy of skin equivalent comprising living cells and skin biodegradable substrate for the treatment of skin lesions</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>study of the efficacy of skin equivalent comprising living cells and skin biodegradable substrate for the treatment of skin lesions</intervention_name>
    <arm_group_label>cell therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The presence of non-healing ulcer at least a month, an area of not less than 3 cm2 or&#xD;
             smaller area of deep defects;&#xD;
&#xD;
          -  Availability of burns II or III level;&#xD;
&#xD;
          -  Epidermolysis bullosa;&#xD;
&#xD;
          -  Availability of post-burn scars&#xD;
&#xD;
          -  Defects in the skin after surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute and chronic diseases in the acute stage;&#xD;
&#xD;
          -  Autoimmune diseases of connective tissue (collagen);&#xD;
&#xD;
          -  Immunodeficiency states;&#xD;
&#xD;
          -  System of inflammatory diseases of the skin;&#xD;
&#xD;
          -  Conduct an aggressive corticosteroid therapy;&#xD;
&#xD;
          -  Acute coronary syndrome;&#xD;
&#xD;
          -  Acute disorders of cerebral circulation;&#xD;
&#xD;
          -  Availability of local inflammation in the acute stage;&#xD;
&#xD;
          -  Pregnancy;&#xD;
&#xD;
          -  Breast-feeding.&#xD;
&#xD;
          -  Positive results of the following tests: Anti-HIV-1 and -2, HIV-1Ag, anti-HTL VI&#xD;
             and-II, anti-HbcorAg, HBs-Ag, anti-HCV, anti-CMV, anti-Toxoplasma gondii, RW,&#xD;
             Neisseria gonorrheae, Chlamydia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oleg G Makeev, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ural State Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arteom V Korotkov</last_name>
    <phone>+73432421546</phone>
    <email>larim@mail.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ural State Medical Academy</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <investigator>
      <last_name>Arteom V Korotkov, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>June 19, 2013</study_first_submitted>
  <study_first_submitted_qc>June 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2013</study_first_posted>
  <last_update_submitted>December 10, 2013</last_update_submitted>
  <last_update_submitted_qc>December 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ural State Medical University</investigator_affiliation>
    <investigator_full_name>Korotkov Artem Vladimirovich</investigator_full_name>
    <investigator_title>Senior Research Fellow</investigator_title>
  </responsible_party>
  <keyword>damage to the skin, the skin equivalent, cell therapy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

